Journal Home
Search for

Volume 2, Issue 4, Pages 327-339 (December 2008)


View previous. 7 of 13 View next.

CAMK1D amplification implicated in epithelial–mesenchymal transition in basal-like breast cancer

Anna Bergamaschiab, Young H. Kimb, Kevin A. Kweib, Yoon La Choibc, Melanie Bocanegrab, Anita Langerøda, Wonshik Hand, Dong-Young Nohd, David G. Huntsmane, Stefanie S. Jeffreyf, Anne-Lise Børresen-Daleag, Jonathan R. PollackbCorresponding Author Informationemail address

Received 15 August 2008; accepted 17 September 2008. published online 20 October 2008.

Abstract 

Breast cancer exhibits clinical and molecular heterogeneity, where expression profiling studies have identified five major molecular subtypes. The basal-like subtype, expressing basal epithelial markers and negative for estrogen receptor (ER), progesterone receptor (PR) and HER2, is associated with higher overall levels of DNA copy number alteration (CNA), specific CNAs (like gain on chromosome 10p), and poor prognosis. Discovering the molecular genetic basis of tumor subtypes may provide new opportunities for therapy. To identify the driver oncogene on 10p associated with basal-like tumors, we analyzed genomic profiles of 172 breast carcinomas. The smallest shared region of gain spanned just seven genes at 10p13, including calcium/calmodulin-dependent protein kinase ID (CAMK1D), functioning in intracellular signaling but not previously linked to cancer. By microarray, CAMK1D was overexpressed when amplified, and by immunohistochemistry exhibited elevated expression in invasive carcinomas compared to carcinoma in situ. Engineered overexpression of CAMK1D in non-tumorigenic breast epithelial cells led to increased cell proliferation, and molecular and phenotypic alterations indicative of epithelial–mesenchymal transition (EMT), including loss of cell–cell adhesions and increased cell migration and invasion. Our findings identify CAMK1D as a novel amplified oncogene linked to EMT in breast cancer, and as a potential therapeutic target with particular relevance to clinically unfavorable basal-like tumors.

a Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, 0310 Oslo, Norway

b Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA

c Department of Pathology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul 135-710, South Korea

d Cancer Research Institute and Department of Surgery, Seoul National University College of Medicine, Seoul 110-744, South Korea

e Department of Pathology, University of British Columbia, and British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada

f Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA

g Faculty of Medicine, University of Oslo, 0316 Oslo, Norway

Corresponding Author InformationCorresponding author at: Department of Pathology, Stanford University, 269 Campus Drive, CCSR-3245A, Stanford, CA 94305-5176, USA. Tel.: +1 650 736 1987.

PII: S1574-7891(08)00124-5

doi:10.1016/j.molonc.2008.09.004


View previous. 7 of 13 View next.